Abstract
BACKGROUND: Dolutegravir (DTG) + lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe. METHODS: To investigate outcomes from other regions, we summarized real-world outcomes with DTG + 3TC in cohorts from Asia and South America. In this systematic literature review, relevant databases and congresses (2013-2023) were searched to identify non-interventional studies reporting DTG + 3TC use; materials reporting effectiveness, safety, or tolerability outcomes were eligible. Post hoc targeted literature searches explored newer and non-English-language materials. RESULTS: From 218 publications identified, 42 representing 23,512 people using DTG + 3TC (naive to antiretroviral therapy (ART), n = 731; switching ART, n = 3159; unspecified, n = 19,622) in China, Japan, Türkiye, Brazil, Taiwan, Russia, Argentina, and South Korea were included. Most virologic effectiveness outcomes were reported at week 48, with virologic suppression rates ranging from 82% to 100% in people naive to ART and 86% to 100% in those switching ART. Among people initiating DTG + 3TC with very high (≥500,000 copies/mL) baseline viral loads, 64% to 95% achieved virologic suppression at week 48. Virologic failure was infrequent. No treatment-emergent resistance was reported. Serious adverse events (1%) and discontinuations due to adverse events (2%) were infrequent. CONCLUSION: In real-world cohorts across Asia and South America, initiating or switching to DTG + 3TC resulted in high proportions of people achieving or maintaining virologic suppression and demonstrated a good safety profile at multiple time points, consistent with clinical trial and real-world data in North America and Europe.